This could offer an interesting opportunity to investigate if these cells with a compromised stress tolerance would be more susceptible to chemotherapeutic agents commonly used in BLCA treatment to mitigate the risk of recurrence, such as mitomycin C. Notably, further studies would include a TRMT6/TRMT61A knockout model system to give more insight into the role of the TRMT6/TRMT61A methyltransferase complex in BLCA. This evidence concerns the gene TRMT61A and bladder transitional cell carcinoma.